
SINT Stock Forecast & Price Target
SINT Analyst Ratings
Bulls say
SINTX Technologies Inc. shows a promising financial outlook, supported by a favorable NPV analysis indicating substantial upside potential from its current share price. The anticipated ramp-up in biomedical commercialization, along with a recent acquisition, enhances growth prospects and is likely to benefit the company's stock performance. Additionally, the anticipated expansion of the global antimicrobial fertilizer and crop protection market, projected to reach up to $10 billion by 2030, presents further opportunities for SINTX's diverse applications in antipathogenic technologies.
Bears say
SINTX Technologies Inc. reported a net loss of $10.3 million, resulting in an earnings per share (EPS) of $(3.46), significantly worse than previous estimates of $(0.55), highlighting concerns over the company's financial performance. Additionally, recurring net losses of $2.3 million and the inability to meet preliminary EPS estimates further exacerbate the negative outlook, reflecting challenges in achieving operational profitability. The investment landscape for SINTX is fraught with risks, including concerns about balance sheet liquidity, regulatory approvals, and broader market sentiment towards biotech and medtech stocks, all of which could hinder the company’s growth potential.
This aggregate rating is based on analysts' research of SINTX Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
SINT Analyst Forecast & Price Prediction
Start investing in SINT
Order type
Buy in
Order amount
Est. shares
0 shares